Skip to content
OpenCapital
Get started

USANA Health Sciences USNA Payments for Repurchase of Common Stock

Payments for Repurchase of Common Stock at other companies

NuSkin Enterprises logo
NuSkin EnterprisesNUS
——
Herbalife logo
HerbalifeHLF
——

Other financials

Income statement

See full
Revenue$250.2M+0.3%
Gross profit$190.8M-3.2%
Operating income$13.9M-11.5%
Net income$7.5M-20.1%
EPS (diluted)$0.41-16.3%

Balance sheet

See full
Cash & equivalents$165.7M-9.2%
Total debt$18.0M+10.8%
Total equity$543.6M+2.6%
Total assets$739.0M-1.0%

Cash flow

See full
Operating cash flow$9.8M-37.0%
CapEx$2.6M-5.6%
Free cash flow$7.1M-43.9%

Valuation

See full
Market cap$394.19M-30.9%
P/E19.7×+8.5×
P/S0.4×-0.2×

Profitability

See full
Gross margin77.6%-3.0pp
Operating margin3.8%-2.7pp
Net margin1.9%-4.4pp
FCF margin5.7%-1.1pp

Returns & leverage

See full
Return on equity3.2%-7.6pp
Debt / equity0×0.0×
Current ratio2.5×+0.5×

Where this comes from

Reported directly by USANA Health Sciences in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: USANA Health Sciences’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about USANA Health Sciences's payments for repurchase of common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is USANA Health Sciences's payments for repurchase of common stock?
USANA Health Sciences (USNA) reported payments for repurchase of common stock of $0 in Q1 2026.
How has USANA Health Sciences's payments for repurchase of common stock changed year-over-year?
USANA Health Sciences's payments for repurchase of common stock decreased by 100.0% year-over-year, from $12.3M to $0.
What does payments for repurchase of common stock mean?
Measures the cash utilized by the company to buy back its own shares from the open market. This is a primary mechanism for returning excess capital to shareholders and often signals management's confidence in the company's valuation.